India
· Delayed Price · Currency is INR Onyx Biotec Statistics
Total Valuation
Onyx Biotec has a market cap or net worth of INR 988.19 million. The enterprise value is 1.27 billion.
| Market Cap | 988.19M |
| Enterprise Value | 1.27B |
Important Dates
The next estimated earnings date is Friday, August 1, 2025.
| Earnings Date | Aug 1, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Onyx Biotec has 18.13 million shares outstanding. The number of shares has increased by 8.08% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 18.13M |
| Shares Change (YoY) | +8.08% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 65.90% |
| Owned by Institutions (%) | n/a |
| Float | 5.91M |
Valuation Ratios
The trailing PE ratio is 15.69.
| PE Ratio | 15.69 |
| Forward PE | n/a |
| PS Ratio | 1.62 |
| PB Ratio | 3.50 |
| P/TBV Ratio | 3.50 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | 28.86 |
| EV / Sales | 2.09 |
| EV / EBITDA | 11.05 |
| EV / EBIT | 15.00 |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.21, with a Debt / Equity ratio of 1.07.
| Current Ratio | 1.21 |
| Quick Ratio | 0.69 |
| Debt / Equity | 1.07 |
| Debt / EBITDA | 2.62 |
| Debt / FCF | n/a |
| Interest Coverage | 3.22 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | n/a |
| Return on Invested Capital (ROIC) | n/a |
| Return on Capital Employed (ROCE) | 17.31% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
| Beta (5Y) | n/a |
| 52-Week Price Change | n/a |
| 50-Day Moving Average | 58.14 |
| 200-Day Moving Average | n/a |
| Relative Strength Index (RSI) | 50.55 |
| Average Volume (20 Days) | 53,000 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Onyx Biotec had revenue of INR 609.58 million and earned 44.17 million in profits. Earnings per share was 3.47.
| Revenue | 609.58M |
| Gross Profit | 219.90M |
| Operating Income | 84.96M |
| Pretax Income | 59.58M |
| Net Income | 44.17M |
| EBITDA | 115.33M |
| EBIT | 84.96M |
| Earnings Per Share (EPS) | 3.47 |
Balance Sheet
The company has 15.18 million in cash and 301.65 million in debt, giving a net cash position of -286.46 million or -15.80 per share.
| Cash & Cash Equivalents | 15.18M |
| Total Debt | 301.65M |
| Net Cash | -286.46M |
| Net Cash Per Share | -15.80 |
| Equity (Book Value) | 282.74M |
| Book Value Per Share | 21.21 |
| Working Capital | 60.36M |
Cash Flow
| Operating Cash Flow | n/a |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
Gross margin is 36.07%, with operating and profit margins of 13.94% and 7.25%.
| Gross Margin | 36.07% |
| Operating Margin | 13.94% |
| Pretax Margin | 9.77% |
| Profit Margin | 7.25% |
| EBITDA Margin | 18.92% |
| EBIT Margin | 13.94% |
| FCF Margin | n/a |
Dividends & Yields
Onyx Biotec does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -8.08% |
| Shareholder Yield | -8.08% |
| Earnings Yield | 4.47% |
| FCF Yield | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | n/a |